These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30408048)

  • 1. AFLP-AFLP in silico-NGS approach reveals polymorphisms in repetitive elements in the malignant genome.
    Koblihova J; Srutova K; Krutska M; Klamova H; Machova Polakova K
    PLoS One; 2018; 13(11):e0206620. PubMed ID: 30408048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
    Soverini S; De Benedittis C; Polakova KM; Linhartova J; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Klamova H; Salvucci M; Crugnola M; Iurlo A; Albano F; Russo D; Rosti G; Cavo M; Baccarani M; Martinelli G
    Oncotarget; 2016 Apr; 7(16):21982-90. PubMed ID: 26980736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico fingerprinting (ISIF): a user-friendly in silico AFLP program.
    Paris M; Després L
    Methods Mol Biol; 2012; 888():55-64. PubMed ID: 22665275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two methods to easily obtain nucleotide sequences from AFLP loci of interest.
    Paris M; Meyer CL; Blassiau C; Coissac E; Taberlet P; Després L
    Methods Mol Biol; 2012; 888():91-108. PubMed ID: 22665277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment.
    Jaruskova M; Curik N; Hercog R; Polivkova V; Motlova E; Benes V; Klamova H; Pecherkova P; Belohlavkova P; Vrbacky F; Machova Polakova K
    J Exp Clin Cancer Res; 2017 Apr; 36(1):55. PubMed ID: 28420426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.
    Baer C; Kern W; Koch S; Nadarajah N; Schindela S; Meggendorfer M; Haferlach C; Haferlach T
    Haematologica; 2016 Jul; 101(7):830-8. PubMed ID: 27102501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
    Ben Hassine I; Gharbi H; Soltani I; Teber M; Farrah A; Ben Hadj Othman H; Amouri H; Bellaaj H; Lakhal RB; Romdhane NB; Abbes S; Menif S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):737-745. PubMed ID: 28286932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M
    Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
    Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amplified fragment length polymorphism: an adept technique for genome mapping, genetic differentiation, and intraspecific variation in protozoan parasites.
    Kumar A; Misra P; Dube A
    Parasitol Res; 2013 Feb; 112(2):457-66. PubMed ID: 23254590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
    Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
    BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
    Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
    Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India.
    Guru SA; Mir R; Bhat M; Najar I; Zuberi M; Sumi M; Masroor M; Gupta N; Saxena A
    Tumour Biol; 2017 Oct; 39(10):1010428317713857. PubMed ID: 29019285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying patterns of DNA for tumor diagnosis using capillary electrophoresis-amplified fragment length polymorphism (CE-AFLP) screening.
    Wong KY; Chuan YC; Aggarwal A; Tham L; Kong WM; Tan P
    J Bioinform Comput Biol; 2004 Sep; 2(3):569-87. PubMed ID: 15359427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATG-anchored AFLP (ATG-AFLP) analysis in cotton.
    Lu Y; Curtiss J; Miranda D; Hughs E; Zhang J
    Plant Cell Rep; 2008 Oct; 27(10):1645-53. PubMed ID: 18584177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance comparison of two reduced-representation based genome-wide marker-discovery strategies in a multi-taxon phylogeographic framework.
    Kirschner P; Arthofer W; Pfeifenberger S; Záveská E; Schönswetter P; ; Steiner FM; Schlick-Steiner BC
    Sci Rep; 2021 Feb; 11(1):3978. PubMed ID: 33597550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
    Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
    Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A repetitive sequence assembler based on next-generation sequencing.
    Lian S; Tu Y; Wang Y; Chen X; Wang L
    Genet Mol Res; 2016 Jul; 15(3):. PubMed ID: 27525861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.